Kindos’ (subsidiary of NKF) Bortezomib for injection getting approved by NMPA, submitted to NMPA and US FDA
April 30, 2024, Bortezomib for injection receives the approval letter by NMPA, formally approved for marketing in China, with independent research and development by Kindos Pharmaceuticals Co., Ltd (Hereinafter referred to ”Kindos”) .
